Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment

A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.

(2022) Komal L. Jhaveri et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer

(2021) Aditya Bardia et al.   JOURNAL OF CLINICAL ONCOLOGY

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis

(2021) Francesco Schettini et al.   Cancers

LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study

(2021) S.A. Hurvitz et al.   ANNALS OF ONCOLOGY

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

(2021) Komal Jhaveri et al.   CLINICAL CANCER RESEARCH

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

(2021) Cristina Hernando et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.

(2021) Marina Maglakelidze et al.   JOURNAL OF CLINICAL ONCOLOGY

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

(2021) Sarat Chandarlapaty et al.   JOURNAL OF CLINICAL ONCOLOGY

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

(2021) A. Gennari et al.   ANNALS OF ONCOLOGY

Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer

(2021) Ya-Chi Chen et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

(2020) Elgene Lim et al.   JOURNAL OF CLINICAL ONCOLOGY

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.

(2020) Cynthia X. Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2019) F Cardoso et al.   ANNALS OF ONCOLOGY

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

(2019) Manuel Ruíz-Borrego et al.   BREAST CANCER RESEARCH AND TREATMENT

Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis

(2019) Mario Giuliano et al.   LANCET ONCOLOGY

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2−Advanced Breast Cancer

(2018) Erika P. Hamilton et al.   CLINICAL CANCER RESEARCH

Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going

(2016) Francesco Schettini et al.   CANCER TREATMENT REVIEWS

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader

(2015) Suzanne E Wardell et al.   ENDOCRINE-RELATED CANCER

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology